BACKGROUND: Preclinical studies confirm that the GABA B agonist, baclofen blocks dopamine release in the reward-responsive ventral striatum (VS) and medial prefrontal cortex, and consequently, blocks drug motivated behavior. Its mechanism in humans is unknown. Here, we used continuous arterial spin labeled (CASL) perfusion fMRI to examine baclofen's effects on blood flow in the human brain. METHODS:Twenty-one subjects (all smokers, 12 females) were randomized to receive either baclofen (80 mg/day; N=10) or placebo (N=11). A five minute quantitative perfusion fMRI resting baseline (RB) scan was acquired at two time points; prior to the dosing regimen (Time 1) and on the last day of 21 days of drug administration (Time 2). SPM2 was employed to compare changes in RB from Time 1 to 2. RESULTS:Baclofen diminished cerebral blood flow (CBF) in the VS and mOFC and increased it in the lateral OFC, a region involved in suppressing previously rewarded behavior. CBF in bilateral insula was also blunted by baclofen (T values ranged from -11.29 to 15.3 at p=0.001, 20 contiguous voxels). CBF at Time 2 was unchanged in placebo subjects. There were no differences between groups in side effects or cigarettes smoked per day (at either time point). CONCLUSIONS:Baclofen's modulatory actions on regions involved in motivated behavior in humans are reflected in the resting state and provide insight into the underlying mechanism behind its potential to block drug-motivated behavior, in preclinical studies, and its putative effectiveness as an anti-craving/anti-relapse agent in humans.
RCT Entities:
BACKGROUND: Preclinical studies confirm that the GABA B agonist, baclofen blocks dopamine release in the reward-responsive ventral striatum (VS) and medial prefrontal cortex, and consequently, blocks drug motivated behavior. Its mechanism in humans is unknown. Here, we used continuous arterial spin labeled (CASL) perfusion fMRI to examine baclofen's effects on blood flow in the human brain. METHODS: Twenty-one subjects (all smokers, 12 females) were randomized to receive either baclofen (80 mg/day; N=10) or placebo (N=11). A five minute quantitative perfusion fMRI resting baseline (RB) scan was acquired at two time points; prior to the dosing regimen (Time 1) and on the last day of 21 days of drug administration (Time 2). SPM2 was employed to compare changes in RB from Time 1 to 2. RESULTS:Baclofen diminished cerebral blood flow (CBF) in the VS and mOFC and increased it in the lateral OFC, a region involved in suppressing previously rewarded behavior. CBF in bilateral insula was also blunted by baclofen (T values ranged from -11.29 to 15.3 at p=0.001, 20 contiguous voxels). CBF at Time 2 was unchanged in placebo subjects. There were no differences between groups in side effects or cigarettes smoked per day (at either time point). CONCLUSIONS:Baclofen's modulatory actions on regions involved in motivated behavior in humans are reflected in the resting state and provide insight into the underlying mechanism behind its potential to block drug-motivated behavior, in preclinical studies, and its putative effectiveness as an anti-craving/anti-relapse agent in humans.
Authors: G Colombo; R Agabio; M A Carai; C Lobina; M Pani; R Reali; G Addolorato; G L Gessa Journal: Alcohol Clin Exp Res Date: 2000-01 Impact factor: 3.455
Authors: S Grant; E D London; D B Newlin; V L Villemagne; X Liu; C Contoreggi; R L Phillips; A S Kimes; A Margolin Journal: Proc Natl Acad Sci U S A Date: 1996-10-15 Impact factor: 11.205
Authors: Teresa R Franklin; Ze Wang; Joshua Shin; Kanchana Jagannathan; Jesse J Suh; John A Detre; Charles P O'Brien; Anna Rose Childress Journal: Brain Struct Funct Date: 2013-01 Impact factor: 3.270
Authors: Kimberly A Young; Teresa R Franklin; David C S Roberts; Kanchana Jagannathan; Jesse J Suh; Reagan R Wetherill; Ze Wang; Kyle M Kampman; Charles P O'Brien; Anna Rose Childress Journal: J Neurosci Date: 2014-04-02 Impact factor: 6.167
Authors: Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Teresa R Franklin; Joshua Shin; Kanchana Jagannathan; Jesse J Suh; John A Detre; Charles P O'Brien; Anna Rose Childress Journal: Drug Alcohol Depend Date: 2012-04-17 Impact factor: 4.492
Authors: Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz Journal: Neuropsychopharmacology Date: 2017-05-31 Impact factor: 7.853